• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Alnylam Pharmaceuticals Inc

+ Add to Watchlist

DUL:GR

50.267 EUR 0.476 0.94%

As of 02:20:04 ET on 08/21/2014.

Snapshot for Alnylam Pharmaceuticals Inc (DUL)

Open: 50.310 Day's Range: 50.267 - 51.320 Volume: 0
Previous Close: 50.743 52wk Range: 34.999 - 80.352 1-Yr Rtn: +38.23%

Stock Chart for DUL

No chart data available.
  • DUL:GR 50.267
  • 1D
  • 1M
  • 1Y
50.743
Interactive DUL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for DUL

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -3.8250
Est. PEG Ratio -
Market Cap (M EUR) 3,838.13
Shares Outstanding (M) 76.35
30 Day Average Volume 100
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/06/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for DUL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for DUL

Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes.

John M MaraganoreChief Executive OfficerBarry E GreenePresident/COO
Akshay K VaishnawExec VP/Chief Medical OfficerLaurence E ReidSenior VP/Chief Business Ofcr
More Company Profile & Key Executives for DUL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil